SUCLA2 and cancer: However, the RB1-defecient status in cancers may turn out to be a disguised blessing for cancer patients as it generates a variety of therapeutic benefits through the upregulation of RB1 targets, the presence of genes which are in a synthetic lethal relationship with RB1, and collateral synthetic lethality due to SUCLA2 loss (Figure 2).